Journals / Turkish Journal of Gastroenterology / 2001 / Cilt: 12 - Sayı: 2

Kronik B ve C hepatitli hastalarda interferon tedavisine yanıtın önceden tahmin edilebilmesinde PCNA indeksinin değeri

Predictive value of proliferating cell nuclear antigen index in response to interferon treatment in patients with chronic viral hepatitis B and C

Pages
89–94
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to these results PCNA-i may be used as a predictive marker for the response to interferon therapy in patients with chronic hepatitis B.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: There are several parameters which may predict the response to interferon therapy in patients with chronic hepatitis B and chronic hepatitis C.
📊
Key Findings & Data:The aim of this study was to evaluate the predictive value of proliferating cell nuclear antigen index (PCAN-i) in determining the response rate to interferon therapy in patients with these infections.
💡
Conclusion & Impact:According to these results PCNA-i may be used as a predictive marker for the response to interferon therapy in patients with chronic hepatitis B.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hepatit B · kronik · Hepatit C

Abstract

Background/Aims: There are several parameters which may predict the response to interferon therapy in patients with chronic hepatitis B and chronic hepatitis C. The aim of this study was to evaluate the predictive value of proliferating cell nuclear antigen index (PCAN-i) in determining the response rate to interferon therapy in patients with these infections. Methods: Twenty-three patients with chronic hepatitis B and 27 with chronic hepatitis C were included in the study. Prior to therapy, liver biopsies were evaluated with respect to Knodell's index and PCNA-i. Results: Histologic activity indices of the patients with chronic hepatitis B and chronic hepatitis C were similar, but the patients with chronic hepatitis B had higher PCNA-i compared to those with chronic hepatitis C (15.4±5.5 vs 11.3±5.0, p=0.009). PCNA-i was significantly lower in non-responders than responders in the chronic hepatitis B group, whereas responders tended to have lower PCNA-i values in patients with chronic hepatitis C. Conclusions: Responders with chronic hepatitis B had elevated PCNA-i, while the patients with chronic hepatitis C who responded to interferon therapy tended to have lower PCNA-i but the reason for that difference is not clear. According to these results PCNA-i may be used as a predictive marker for the response to interferon therapy in patients with chronic hepatitis B.

Özet

Amaç:Kronik hepatit B ve kronik hepatit C'li hastaların interferon tedavisine verecekleri yanıtın önceden tahmin edilebilmesi için kullanılan çeşitli parametreler vardır. Çalışmamızda kronik hepatit B ve kronik hepatit C'li hastalarda interferon tedavisi ile elde edilen yanıtı tahmin edebilmede PCNA-i'nin prediktif değerinin araştırılması amaçlanmıştır. Yöntem: Çalışmaya 23 kronik hepatit B ve 27 kronik hepatit C'li hasta dahil edilmiştir. Çalışma öncesi tüm hastalardan karaciğer biopsileri alınmış ve Knodell's indeksleri ve PCNA-i'leri belirlenmiştir. Bulgular: Kronik hepatit B ve kronik hepatit C'li hastaların histolojik aktivite indeksleri arasında fark bulunmazken, PCNA-i KHB'li grupta kronik hepatit C'li gruba göre daha yüksek bulunmuştur (15.4±5.5 vs 11.3±5.0, p=0.009). Kronik hepatit B'li grupta tedavi yanıtı olmayan hastalarda PCNA-i tedaviye yanıtlı hastalara kıyasla anlamlı şekilde daha düşük bulunmuştur. Kronik hepatit C'li grupta ise tedaviye yanıt veren hastalarda PCNA-i'nin daha düşük olma eğiliminde olduğu görülmüş ancak aradaki fark istatistiksel anlamlılık göstermemiştir. Sonuç: kronik hepatit B'li hastalardan tedaviye yanıtlı olanlarda PCNA-i değeri yüksek bulunurken KHC'li hastalardan tedavi yanıtı gösterenlerde PCNA-i düşük saptanmıştır. Bu farkın sebebi bilinmemekle birlikte bu sonuçlar kronik hepatit B'li hastalarda PCNA-i'nin interferon tedavisine yanıtı önceden tahmin etmede yardımcı olabileceğini düşündürmektedir.

🔖

Cite This Article

KARASU, Z., BARBET, F. Y., ERSÖZ, G., GÜNŞAR, F., BATUR, Y., AKARCA, U. S. (2001). Kronik B ve C hepatitli hastalarda interferon tedavisine yanıtın önceden tahmin edilebilmesinde PCNA indeksinin değeri. Turkish Journal of Gastroenterology, Cilt: 12 - Sayı: 2, 89–94. https://ajindex.com/articles/411234

References (14)

  1. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized double blind placebo controlled trial. N Eng J Med 1989; 321: 1506-10
  2. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-25
  3. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-a2b treatment for hepatitis Be antigen positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75
  4. Perillo RP. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology 1990; 12: 1433-35
  5. Booth JCL, Foster GR, Kumar U, et al. Chronic hepatitis C virus infections: predictive value of genotype and level of viremia on disease progression and response to interferon-a. Gut 1995; 36: 427-32
  6. McCaughan GW, Gorrell MD, Bishop GA, et al. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev 2000; 174: 172-91
  7. Wolf HK, Michalopoulos GK. Hepatocyte regeneration in acute fulminant and non-fulminant hepatitis: a study of proliferating cell nuclear antigen expression. Hepatology 1992; 15: 707-13
  8. Knodell RG, Ishak G, Back C, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981: 1: 431
  9. Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-94
  10. Chisari FV, Ferrari C. Immunobiology and pathogenesis of viral hepatitis. In: Nathenson N, Ahmed R, Gonzales Scanaro F, eds. Viral pathogenesis, New York, NY, Raven Press, 1995
  11. Chisari FV. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995; 22: 1316-25
  12. Thomas HC, Karayiannis P, Brook G. Treatment of hepatitis B virus infection with interferon. Factors predicting the response to interferon. J Hepatol 1991; 13: 4-7
  13. Gaeta GB, Nardiello S, Pizzella T, et al. Semiquantitative anti HbcIgM detection in children with chronic hepatitis B: a long term follow up study. J Med Virol 1995; 46: 173-7
  14. Hoofnagle JH. Alpha interferon therapy of chronic hepatitis B. Current status and recommendation